Thyroid Antibodies Decoded: Which to Order, When They Matter, and When They Don't

 

Thyroid Antibodies Decoded: Which to Order, When They Matter, and When They Don't

Three antibodies, three different clinical stories—and the autoimmune crossover that ties them to everything else you're managing.

Thyroid antibody testing is one of the most commonly ordered—and most commonly misinterpreted—panels in primary care. Every week I see providers ordering the full antibody panel on every patient with an abnormal TSH, or panicking about a positive anti-TPO in someone with a perfectly normal thyroid. Let's sort out what each antibody actually tells you and when it changes your management.

The Three Thyroid Antibodies

Anti-TPO (Thyroid Peroxidase Antibody)

Target: Thyroid Peroxidase Enzyme

The workhorse antibody for Hashimoto's thyroiditis. TPO is the enzyme that catalyzes thyroid hormone synthesis. Anti-TPO antibodies activate complement and are directly involved in thyroid tissue destruction. Present in ~95% of Hashimoto's patients and ~70% of Graves' patients. This is the most sensitive thyroid antibody for detecting autoimmune thyroid disease (AITD).

The catch: anti-TPO is also positive in about 10% of the general population who have no thyroid disease—and this prevalence rises with age and female sex. A positive anti-TPO alone, without thyroid dysfunction, doesn't require treatment.

Anti-Tg (Thyroglobulin Antibody)

Target: Thyroglobulin Protein

Present in 30–50% of Hashimoto's patients and at about half that rate in Graves' disease. Less sensitive than anti-TPO for diagnosing AITD. Per Mayo Clinic Laboratories guidance, anti-Tg should only be ordered if anti-TPO is negative but clinical suspicion for AITD remains high.

Critical second role: Anti-Tg is essential in the monitoring of differentiated thyroid cancer after treatment. Thyroglobulin (Tg) is used as a tumor marker post-thyroidectomy, but anti-Tg antibodies interfere with the Tg assay—causing falsely low results on immunometric assays. If anti-Tg is present, the Tg tumor marker is unreliable, and rising anti-Tg titers themselves may indicate recurrence.

TRAb / TSI (TSH Receptor Antibodies / Thyroid-Stimulating Immunoglobulin)

Target: TSH Receptor

The Graves' disease antibody. TSI binds to the TSH receptor and mimics TSH, causing unregulated thyroid hormone production. TSI is ~96% sensitive and ~99% specific for Graves' disease. There are actually three types of TSH receptor antibodies—stimulating (TSI), blocking, and neutral—but TSI is the clinically actionable one.

Nomenclature warning: TRAb, TBII, TSI, and LATS all refer to related but distinct assays. TRAb/TBII measures all receptor antibodies (stimulating + blocking + neutral). TSI measures only the stimulating type. In most clinical contexts, TSI is what you want when confirming Graves' disease.

The Master Decision Table: Which Antibody, When

Clinical Scenario	What to Order	Why
Elevated TSH, suspect Hashimoto's	Anti-TPO	Most sensitive marker; confirms autoimmune etiology. Anti-Tg adds little if TPO is positive.
Elevated TSH, anti-TPO negative, still suspect AITD	Anti-Tg	~5% of Hashimoto's patients are TPO-negative but Tg-positive
Subclinical hypothyroidism (mildly elevated TSH, normal T4)	Anti-TPO	Positive anti-TPO predicts progression to overt hypothyroidism; may influence treatment decision
Suppressed TSH, suspect Graves' disease	TSI (or TRAb)	Confirms Graves' vs. other causes of hyperthyroidism (toxic nodule, thyroiditis, exogenous T4)
Hyperthyroidism when radioactive iodine uptake is contraindicated or unavailable	TSI	Can confirm Graves' without imaging
Pregnant with Graves' disease (or history of Graves')	TRAb/TSI	Maternal TRAb crosses the placenta; high titers predict neonatal thyrotoxicosis risk
Post-thyroidectomy thyroid cancer monitoring	Anti-Tg (with every thyroglobulin measurement)	Anti-Tg interferes with Tg tumor marker assays; rising anti-Tg may signal recurrence
Positive ANA workup, looking for cause	Anti-TPO + Anti-Tg	Thyroid antibodies may be the sole explanation for ANA positivity (speckled or homogeneous pattern)
Euthyroid patient, no symptoms	Nothing	Don't screen asymptomatic patients for thyroid antibodies

The Pitfalls: What Trips Up Clinicians

1. Positive Anti-TPO in a Euthyroid Patient ≠ Disease

About 10% of the general population—and up to 25% of women over 60—will have positive anti-TPO with completely normal thyroid function. This does not require treatment. It does mean the patient has a higher risk of developing overt hypothyroidism over time (about 2–4% per year if TSH is already in the high-normal range). The appropriate response is periodic TSH monitoring, not levothyroxine.

Clinical Pearl

The combination of positive anti-TPO + mildly elevated TSH is where the treatment decision gets nuanced. Many endocrinologists will recommend starting levothyroxine in this scenario, especially if the patient is symptomatic, has a goiter, is trying to conceive, or has TSH >10. Antibody-negative subclinical hypothyroidism is less likely to progress and may be observed.

2. Don't Routinely Order Anti-Tg for Hashimoto's Diagnosis

Anti-TPO is more sensitive and has equal specificity. Ordering both together for initial diagnosis adds cost without meaningful diagnostic yield. Save anti-Tg for when TPO is negative but suspicion is high, or for thyroid cancer monitoring.

3. Thyroid Antibodies Can Explain a Positive ANA

This was highlighted in the Bellocchi autoimmune serologic testing review that started this whole blog series. Anti-TPO and anti-Tg antibodies can cause ANA positivity, typically with a speckled or homogeneous pattern. In a patient with positive ANA but no clinical features of CTD, always check thyroid antibodies. Hashimoto's may be the sole explanation—and it's far more common than lupus.

Connecting the Dots

If you're working up a positive ANA and the patient has no joint pain, no rash, no Raynaud's, and no oral ulcers—but they do have fatigue and a TSH of 6.2—check anti-TPO before chasing an ENA panel. You may save the patient a rheumatology referral.

4. TSI vs. TRAb: Know What You're Ordering

The nomenclature is genuinely confusing. TRAb (or TBII) assays measure all TSH receptor antibodies—stimulating, blocking, and neutral. TSI assays specifically measure only stimulating antibodies. For confirming Graves' disease, TSI is more specific. Some labs report "TRAb" when they mean TBII; others use TRAb to mean TSI. Know what your lab is actually running, and when in doubt, specifically order TSI.

5. Graves' Disease Patients Can Be TRAb/TSI-Negative (Rarely)

About 5% of Graves' patients are seronegative for TSI. If the clinical picture is classic (suppressed TSH, elevated free T4, diffuse goiter, ophthalmopathy) but TSI is negative, a radioactive iodine uptake scan will confirm the diagnosis. Don't exclude Graves' based solely on a negative antibody.

6. Biotin Interference

This is a practical pitfall that catches people. Biotin (vitamin B7)—found in many hair, skin, and nail supplements—can interfere with immunoassays used for thyroid testing, including antibody tests. It can cause falsely low TSH and falsely high free T4 (mimicking hyperthyroidism), and can interfere with antibody measurements. Patients should stop biotin supplements for at least 12 hours (some labs recommend 48–72 hours) before thyroid testing.

7. Pregnancy: When Antibodies Really Matter

Thyroid antibodies take on special significance in pregnancy:

• Positive anti-TPO in euthyroid pregnant women increases risk of miscarriage and preterm birth. Some guidelines recommend levothyroxine in this population, though this remains debated.
• TRAb/TSI in pregnant women with Graves' disease (active or history of Graves'): these antibodies cross the placenta and can cause neonatal thyrotoxicosis. Check TRAb/TSI in early pregnancy and again at 18–22 weeks; high titers warrant neonatal monitoring.
• Postpartum thyroiditis: anti-TPO positive women have a significantly higher risk of developing postpartum thyroiditis. Persistently elevated antibodies after postpartum thyroiditis predict permanent hypothyroidism.

8. Immune Checkpoint Inhibitor Thyroiditis

For NPs managing oncology patients: immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) frequently cause thyroid adverse effects. Patients with pre-existing thyroid antibodies are at higher risk. Checking anti-TPO before starting immunotherapy can help predict who will develop thyroiditis, and thyroid function should be monitored throughout treatment.

The Autoimmune Cluster

Autoimmune thyroid disease rarely travels alone. If you diagnose Hashimoto's or Graves', keep these associated conditions on your radar:

• Type 1 diabetes — screen if symptomatic
• Celiac disease — consider if GI symptoms, anemia, or weight changes
• Pernicious anemia — check B12 and anti-intrinsic factor if macrocytic anemia
• Vitiligo, alopecia areata — skin manifestations of shared autoimmune susceptibility
• Addison's disease — rare but part of autoimmune polyglandular syndrome
• SLE, Sjögren's, RA — broader CTD spectrum
• Primary Raynaud's — may be associated with autoimmune thyroiditis

Quick-Reference: The Ordering Algorithm

TSH Result	Clinical Question	Order
Elevated (hypo)	Is this autoimmune?	Anti-TPO. If negative, consider anti-Tg.
Mildly elevated (subclinical)	Will this progress?	Anti-TPO (positive = higher risk of progression)
Suppressed (hyper)	Is this Graves'?	TSI (or TRAb). Do NOT use anti-TPO to diagnose Graves'.
Normal	ANA positive, no CTD features	Anti-TPO + anti-Tg (thyroid antibodies may explain ANA)
Normal	No symptoms, no clinical indication	Don't order thyroid antibodies
Any	Pregnant with Graves' (active or history)	TRAb/TSI (1st trimester and 18–22 weeks)
Any	Thyroid cancer monitoring post-treatment	Anti-Tg (with every thyroglobulin tumor marker)

Bottom Line

Thyroid antibody testing is powerful when used correctly. Anti-TPO is your go-to for Hashimoto's and subclinical hypothyroidism risk stratification. TSI is what confirms Graves'. Anti-Tg is a niche player—reserve it for TPO-negative suspected AITD and thyroid cancer monitoring. And remember: a positive antibody in a euthyroid patient is not a diagnosis. It's a risk factor that requires monitoring, not reflexive treatment.

Most importantly for this series: thyroid antibodies are the hidden explanation behind many "unexplained" positive ANAs. If you take nothing else from this post, remember to check anti-TPO and anti-Tg when you're chasing a positive ANA in a patient who just doesn't look like lupus.

Stay sharp out there.

The Celiac Serologic Panel: Getting It Right the First Time

 

The Celiac Serologic Panel: Getting It Right the First Time

Two tests, one massive pitfall, and the number-one mistake that makes the whole workup useless.

Celiac disease affects roughly 1 in 100 people, but up to 80% of cases remain undiagnosed. It masquerades as IBS, iron deficiency anemia, unexplained osteoporosis, chronic fatigue, infertility, and even "normal" GI symptoms that patients have lived with for years. The serologic panel is straightforward—but there are pitfalls that will make you miss the diagnosis entirely if you don't know them.

Let's get this one right.

The Tests: What to Order and Why

The First-Line Screen: tTG-IgA + Total IgA

That's it. For most patients over age 2, you need exactly two tests:

1

tTG-IgA (Tissue Transglutaminase IgA Antibody)
The preferred screening test per ACG, AGA, and ESPGHAN guidelines. Sensitivity of 93–98%, specificity of 96–98%. This is the workhorse of celiac diagnosis. If it's positive, you're on the right track. If it's strongly positive (>10× upper limit of normal), that alone may be sufficient for diagnosis in children without biopsy (per ESPGHAN criteria).

2

Total Serum IgA
This is the test that gets forgotten—and it's the one that saves you from a false negative. Selective IgA deficiency occurs in 2–3% of celiac patients (compared to 1 in 400–800 in the general population). If your patient is IgA-deficient, every IgA-based celiac test will be falsely negative. You need this result to know whether you can trust the tTG-IgA.

The #1 Mistake

Ordering tTG-IgA without a total IgA level. If your patient happens to be IgA-deficient, a negative tTG-IgA means nothing. You've just given them a false all-clear for celiac disease. Always order both together.

When IgA Is Deficient: The IgG Backup Panel

If total IgA is low or undetectable, switch to IgG-based tests:

• DGP-IgG (Deamidated Gliadin Peptide IgG) — the preferred IgG test in the setting of IgA deficiency. Slightly better sensitivity than tTG-IgG.
• tTG-IgG — less specific than tTG-IgA; should only be used if IgA deficiency is confirmed. In IgA-sufficient patients, tTG-IgG has an unacceptably high false-positive rate.
• EMA-IgG (Endomysial Antibody IgG) — highly specific but expensive and observer-dependent. Available at some centers.

Key Rule

Never order tTG-IgG in an IgA-sufficient patient. Per AGA best practice advice, IgG isotype testing for tTG is not specific in the absence of IgA deficiency. It will generate false positives and unnecessary endoscopies.

The Other Tests You'll See on Panels

Test	Role	When to Use
tTG-IgA	First-line screening	All patients ≥2 years with suspected celiac disease
Total IgA	Rule out IgA deficiency	Always order alongside tTG-IgA
DGP-IgG	Best IgG alternative	When IgA deficiency is confirmed; also useful in children <2
tTG-IgG	IgG backup	Only in confirmed IgA deficiency (high false-positive rate otherwise)
EMA-IgA	Confirmatory test (~100% specificity)	To confirm a positive tTG-IgA, especially if tTG is >10× ULN (biopsy-free pathway in children)
DGP-IgA	Secondary test	No advantage over tTG-IgA for initial screening; higher false-positive rate
HLA-DQ2/DQ8	Rule-out test (excellent negative predictive value)	If negative, celiac is virtually excluded. Does NOT confirm celiac if positive (30–40% of the general population carries these alleles)

The Pitfalls: Where Clinicians Go Wrong

1. Testing While the Patient Is Already Gluten-Free

This is the single most destructive mistake in celiac testing. If the patient has already eliminated or significantly reduced gluten, both serology and biopsy may be falsely negative. Antibody levels decline within weeks to months on a gluten-free diet (GFD), and villous atrophy can begin healing.

Critical Rule

Do NOT allow the patient to start a GFD before completing the diagnostic workup. If they've already started one, they need a gluten challenge (consuming gluten daily for at least 2–6 weeks, ideally 6–12 weeks) before testing. Many patients are unwilling to do this after they've felt better gluten-free—which is why getting the testing done first is so important.

2. Forgetting Total IgA

Worth repeating: 2–3% of celiac patients are selectively IgA-deficient. Without checking total IgA, you may reassure an IgA-deficient celiac patient that they don't have the disease. This is a preventable miss.

3. Ordering the Full Panel Instead of the Right Tests

Many labs offer "celiac panels" that include tTG-IgA, tTG-IgG, DGP-IgA, DGP-IgG, and sometimes EMA. Per the AAFP Choosing Wisely recommendation, don't order tTG-IgG or DGP antibodies as initial screening tests. They have higher false-positive rates and add cost without improving diagnostic accuracy in IgA-sufficient patients. Start with tTG-IgA + total IgA. Add IgG tests only if IgA deficiency is confirmed.

4. Low-Positive tTG-IgA Results

False-positive tTG-IgA results occur, typically at low titers (1–2× the upper limit of normal). These can be seen in type 1 diabetes, autoimmune thyroid disease, autoimmune liver disease, heart failure, and other inflammatory conditions. A low-positive tTG-IgA should be confirmed with EMA or repeated before committing the patient to endoscopy. Strongly positive results (>10× ULN) are much more reliable.

5. Assuming a Positive Serology = Celiac Disease

In adults, a positive tTG-IgA should lead to referral for endoscopic duodenal biopsy to confirm the diagnosis before starting a GFD. Serology alone is not diagnostic in adults per current ACG guidelines. In children and adolescents, the ESPGHAN guidelines do allow a biopsy-free diagnosis if tTG-IgA is >10× ULN AND EMA-IgA is positive on a second, separate blood draw—but this decision should be made by a pediatric gastroenterologist.

6. Children Under 2: Use DGP Too

In very young children, tTG-IgA may be less sensitive. ACG guidelines recommend adding DGP-IgA and DGP-IgG to the workup in children under 2 years of age. The immune response to gluten takes time to develop, and these children need to have been eating gluten-containing foods for a sufficient period before testing will be accurate.

7. HLA Testing: Great for Ruling OUT, Not for Ruling IN

HLA-DQ2 and HLA-DQ8 are present in virtually all celiac patients. But they're also carried by 30–40% of the general population, most of whom will never develop celiac disease. The value of HLA testing is its negative predictive value: if a patient is DQ2/DQ8-negative, celiac disease is essentially excluded. This is particularly useful for first-degree relatives being considered for lifelong screening, or for patients already on a GFD where serology is unreliable.

Who Should Be Tested?

Test When You See

• Chronic or recurrent diarrhea, bloating, abdominal pain (especially if labeled "IBS")
• Unexplained iron deficiency anemia (especially if refractory to supplementation)
• Unexplained weight loss or failure to thrive in children
• Unexplained osteoporosis or osteopenia, particularly in premenopausal women or men
• Dermatitis herpetiformis (intensely pruritic blistering rash on elbows, knees, buttocks—this IS celiac disease of the skin)
• Recurrent aphthous stomatitis (canker sores)
• Unexplained elevated transaminases
• Peripheral neuropathy without other explanation
• Dental enamel defects
• Unexplained infertility or recurrent miscarriage
• First-degree relatives of celiac patients
• Type 1 diabetes (associated autoimmune condition—screen if symptomatic)
• Autoimmune thyroid disease, Down syndrome, Turner syndrome, Williams syndrome

Do NOT Test

• As population screening in asymptomatic, low-risk individuals
• While the patient is already on a GFD (results will be unreliable)
• With tTG-IgG or DGP as first-line tests in IgA-sufficient patients

The Autoimmune Connection

This is where celiac testing intersects with the rest of this blog series. Celiac disease clusters with other autoimmune conditions:

• Type 1 diabetes — 3–8% of T1D patients have celiac disease
• Hashimoto's thyroiditis and Graves' disease — increased prevalence
• Autoimmune liver disease — celiac can cause cryptogenic transaminitis
• Sjögren's syndrome, SLE, RA — shared autoimmune susceptibility
• Selective IgA deficiency — both associated with celiac AND causes false-negative testing
• Dermatitis herpetiformis — the skin manifestation of celiac disease; always biopsy the uninvolved skin adjacent to the lesion (direct immunofluorescence shows granular IgA deposits at the dermal papillae)

If you're working up one autoimmune condition, keep celiac in the differential—especially if the patient has unexplained anemia, GI symptoms, or weight changes.

Monitoring After Diagnosis

Once celiac disease is confirmed and a GFD is started:

• Recheck tTG-IgA (or DGP-IgG if IgA-deficient) at 3–6 months after diagnosis
• Continue checking every 6 months until levels normalize
• Then annually to monitor GFD adherence
• Persistent or rising antibodies suggest ongoing gluten exposure (intentional or inadvertent)
• Screen for nutritional deficiencies at diagnosis: iron, B12, folate, vitamin D, calcium, zinc
• Repeat DEXA scan if osteopenia/osteoporosis was present at diagnosis

Quick-Reference: The Celiac Testing Algorithm

Scenario	What to Order	Next Step
Standard screen (age ≥2)	tTG-IgA + total IgA	If tTG-IgA positive → refer GI for biopsy
IgA deficient	DGP-IgG (± tTG-IgG)	If positive → refer GI for biopsy
Children <2 years	tTG-IgA + DGP-IgA + DGP-IgG + total IgA	Refer pediatric GI for interpretation
Low-positive tTG-IgA (1–2× ULN)	Confirm with EMA-IgA or repeat tTG-IgA	If confirmed → refer for biopsy. If negative on repeat → likely false positive
Already on GFD	HLA-DQ2/DQ8 (to rule out), or gluten challenge then serology	If HLA negative → celiac excluded. If HLA positive → need gluten challenge for definitive testing
Monitoring on GFD	tTG-IgA (or DGP-IgG if IgA-deficient)	Every 6 months until normal, then annually

Bottom Line

Celiac testing is deceptively simple: two tests will get you there in most cases. But the pitfalls are real—forgetting total IgA, testing on a GFD, ordering the wrong IgG tests in IgA-sufficient patients, and accepting low-positive results without confirmation. Get the order right, make sure the patient is still eating gluten, and always check that total IgA.

For your autoimmune patients especially, celiac disease should live permanently on your differential diagnosis list. It's common, it's underdiagnosed, and it's one of the few autoimmune conditions where the treatment—a gluten-free diet—can fully control the disease.

Stay sharp out there.

The Myositis Antibody Panel: Decoding the Alphabet Soup of Inflammatory Muscle Disease

 

The Myositis Antibody Panel: Decoding the Alphabet Soup of Inflammatory Muscle Disease

When your patient has unexplained elevated CPK and weakness, these antibodies tell you what you're really dealing with—and what's coming next.

Here's a scenario every primary care NP has seen: a patient comes in with fatigue, proximal weakness, and a CPK that's through the roof. The reflexive move is to think statin myopathy, rhabdomyolysis, or maybe hypothyroid myopathy. But what if the CPK stays elevated, the weakness progresses, and the usual suspects are ruled out?

That's when you need to think about idiopathic inflammatory myopathies (IIM)—and the myositis-specific antibody panel becomes your most powerful diagnostic tool.

The Big Picture: What Are Inflammatory Myopathies?

The IIMs are a group of autoimmune diseases that attack skeletal muscle. They include:

• Dermatomyositis (DM) — muscle weakness plus characteristic skin findings (heliotrope rash, Gottron's papules, V-sign, shawl sign)
• Polymyositis (PM) / Antisynthetase Syndrome (AS) — proximal weakness, interstitial lung disease (ILD), arthritis, Raynaud's, mechanic's hands. Note: "polymyositis" as a standalone diagnosis is increasingly rare; most cases reclassify into antisynthetase syndrome, IMNM, or inclusion body myositis with modern testing
• Immune-Mediated Necrotizing Myopathy (IMNM) — severe weakness with very high CPK, necrotizing pathology on biopsy, often associated with statin exposure
• Inclusion Body Myositis (IBM) — typically affects older men, distal and proximal weakness, poor response to immunosuppression. No reliable MSA marker.

Each subtype has distinct antibody associations, which predict clinical phenotype, organ involvement, cancer risk, and prognosis. This is why the panel matters so much.

Myositis-Specific vs. Myositis-Associated Antibodies

An important distinction first:

• Myositis-Specific Antibodies (MSA) — about 90% specific for IIM. They are generally mutually exclusive (a patient typically has only one). Finding two or more MSAs simultaneously should raise suspicion for a false positive.
• Myositis-Associated Antibodies (MAA) — found in myositis patients but also in other CTDs (SLE, scleroderma, Sjögren's). These include anti-Ro52, anti-U1-RNP, and anti-PM/Scl. Helpful for identifying overlap syndromes but not diagnostic for myositis on their own.

Key Concept

Approximately 50% of patients with IIM will have a detectable MSA. The other 50% are seronegative. A negative myositis panel does NOT rule out myositis. Diagnosis still requires clinical assessment, CPK levels, EMG/MRI, and often muscle biopsy.

The Antibodies: What Each One Tells You

The Antisynthetase Antibodies (Antisynthetase Syndrome)

These target aminoacyl-tRNA synthetase enzymes. The clinical syndrome they define—antisynthetase syndrome—is characterized by myositis, interstitial lung disease (ILD), non-erosive arthritis, Raynaud's phenomenon, mechanic's hands (cracked, fissured skin on the lateral fingers), and fever.

Anti-Jo-1

Target: Histidyl-tRNA Synthetase

The most common MSA overall, found in 15–25% of PM/DM patients. The only MSA included in the 2017 EULAR/ACR IIM classification criteria. Strongly associated with ILD, arthritis, mechanic's hands, and Raynaud's. Generally predicts a better response to steroids than some other MSAs, but ILD can still be severe and progressive.

Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-KS, Anti-Zo, Anti-Ha

Target: Other Aminoacyl-tRNA Synthetases

Each is individually rare (1–5% prevalence), but collectively they define the same antisynthetase syndrome spectrum. Anti-PL-7 and anti-PL-12 are the most clinically significant after Jo-1. Anti-PL-12 in particular may present as ILD without significant myositis—don't wait for CPK elevation to suspect it.

Dermatomyositis-Specific Antibodies

Anti-Mi-2

Target: Nucleosome Remodeling Deacetylase Complex

The classic DM antibody. Associated with the "textbook" DM presentation: heliotrope rash, Gottron's papules, proximal weakness. Good prognosis. Typically responds well to standard immunosuppressive therapy. Lower risk of ILD and malignancy compared to other DM antibodies.

Anti-TIF1γ (Anti-p155/140)

Target: Transcription Intermediary Factor 1γ

⚠ CANCER SCREENING REQUIRED. Found in 20–30% of adult DM patients. In adults, this antibody carries a strong association with occult malignancy (up to 40–80% of adult patients in some series). Any adult with positive anti-TIF1γ needs comprehensive cancer screening at diagnosis and ongoing surveillance. In children, this antibody is associated with severe skin disease but NOT cancer.

Anti-NXP-2 (Anti-MJ)

Target: Nuclear Matrix Protein 2

⚠ CANCER SCREENING REQUIRED IN ADULTS. Associated with DM in both children and adults. In children, strongly linked to calcinosis (calcium deposits in soft tissues). In adults, carries an increased risk of malignancy, similar to anti-TIF1γ, though data is still evolving. Also associated with severe myopathy, dysphagia, and subcutaneous edema.

Anti-MDA5 (Anti-CADM-140)

Target: Melanoma Differentiation-Associated Gene 5

⚠ RAPIDLY PROGRESSIVE ILD — THIS IS AN EMERGENCY. Specific for DM, particularly clinically amyopathic DM (skin findings without significant muscle weakness or CPK elevation). The hallmark complication is rapidly progressive interstitial lung disease that can be fatal within weeks to months without aggressive treatment. Also associated with painful skin ulcers, palmar papules, and arthritis. If you see this antibody, the patient needs pulmonology and rheumatology urgently.

Anti-SAE

Target: Small Ubiquitin-Like Modifier Activating Enzyme

Rare. Associated with DM that often begins with skin manifestations and progresses to muscle involvement over time. In adults, also carries an increased cancer risk. Dysphagia is common.

Necrotizing Myopathy Antibodies

Anti-SRP

Target: Signal Recognition Particle

Associated with immune-mediated necrotizing myopathy (IMNM). Severe, acute-onset proximal weakness with very high CPK (often >10,000). Biopsy shows necrosis with minimal inflammation. Often treatment-resistant—may require aggressive immunosuppression (IVIG, rituximab). Can have cardiac involvement. In children, may mimic muscular dystrophy with slowly progressive weakness.

Anti-HMGCR

Target: HMG-CoA Reductase

The statin-associated myopathy antibody—but it can also occur in statin-naïve patients. Causes IMNM with very high CPK. This is NOT regular statin myalgia. Stopping the statin alone is insufficient; these patients require immunosuppressive therapy. Important: anti-HMGCR is NOT included in most standard myositis panels and must be ordered separately.

The Master Reference Table

Antibody	Disease	Key Clinical Features	Red Flag
Anti-Jo-1	Antisynthetase syndrome	Myositis, ILD, arthritis, mechanic's hands, Raynaud's	ILD can be severe and progressive
Anti-PL-7/PL-12	Antisynthetase syndrome	ILD-predominant; PL-12 may present as ILD without myositis	Don't wait for elevated CPK
Anti-Mi-2	Dermatomyositis	Classic DM rash + weakness; good steroid response	Best prognosis of the DM antibodies
Anti-TIF1γ	Dermatomyositis	Skin-predominant DM in adults	Cancer screening mandatory in adults
Anti-NXP-2	Dermatomyositis	Calcinosis (children), severe myopathy, dysphagia	Cancer risk in adults; calcinosis in children
Anti-MDA5	Amyopathic DM	Skin ulcers, palmar papules, minimal muscle involvement	Rapidly progressive ILD — emergency
Anti-SAE	Dermatomyositis	Skin-first DM progressing to myositis, dysphagia	Cancer risk in adults
Anti-SRP	IMNM	Severe acute weakness, very high CPK, cardiac risk	Treatment-resistant; needs aggressive immunosuppression
Anti-HMGCR	IMNM	Statin-associated (or statin-naïve) necrotizing myopathy	Must order separately; stopping statin is not enough

The Pitfalls: What Trips Up Clinicians

1. Elevated Transaminases ≠ Liver Disease

This was covered in the autoimmune serologic testing review too, and it bears repeating. AST is released from both liver and muscle. A patient with inflammatory myopathy may present with elevated AST and ALT and get sent to hepatology. Always check CPK when transaminases are elevated without clear liver disease. If CPK is significantly elevated, you're looking at muscle, not liver.

Don't Miss This

A patient referred for "unexplained elevated transaminases" who also has proximal weakness, rash, or arthritis needs a CPK and a myositis workup—not a liver biopsy.

2. Weak Positives on Immunoblot Panels Are Unreliable

Most commercial myositis panels use line immunoassay (immunoblot), which reports results as negative, weak positive, or strong positive. Recent studies show that weak positives have a high false-positive rate—more than 1 in 10 patients with non-myositis diseases can show a weak positive. Strong positives are much more clinically meaningful. Always correlate with clinical presentation.

3. MSAs Are Mutually Exclusive (Usually)

If your patient's panel comes back positive for two or more MSAs, be skeptical. True dual-positive MSAs are rare. This pattern is more likely to represent assay cross-reactivity or a false positive, especially with immunoblot-based assays. Discuss with rheumatology before acting on it.

4. Anti-HMGCR Must Be Ordered Separately

This is a huge miss in practice. A patient with statin exposure, very high CPK, and progressive weakness who doesn't improve after stopping the statin may have anti-HMGCR IMNM—but the standard myositis panel won't detect it. You have to specifically order anti-HMGCR antibody. If your patient had statin-associated symptoms that didn't resolve, order this test.

5. Seronegative Myositis Is Real

About half of IIM patients are MSA-negative. A negative panel does not exclude the diagnosis. If the clinical picture is strong (progressive proximal weakness, high CPK, characteristic rash, compatible EMG/MRI findings), the patient still needs referral and likely a muscle biopsy.

6. Don't Use the Myositis Panel as a Screening Test

Ordering an extended myositis panel for vague fatigue or mild CPK elevation without clinical features of IIM will generate false positives and unnecessary anxiety. This is a targeted test for patients with a meaningful pretest probability of inflammatory myopathy.

7. Cancer Screening with Specific Antibodies

Anti-TIF1γ, anti-NXP-2, and anti-SAE in adults carry a significant association with occult malignancy. Cancer screening at diagnosis should include age- and sex-appropriate screenings plus CT of chest, abdomen, and pelvis. Some centers add PET-CT. Screening should be repeated at 3–5 years for high-risk antibodies, as cancers can present after the myositis diagnosis.

When Should NPs Order the Myositis Panel?

Order When You See

• Progressive proximal muscle weakness (difficulty rising from chairs, climbing stairs, lifting arms overhead)
• Significantly elevated CPK (especially >5× normal) without clear mechanical or pharmacologic cause
• Characteristic DM skin findings: heliotrope rash (purple eyelid discoloration), Gottron's papules (scaly plaques over knuckles), V-sign, shawl sign
• Mechanic's hands + Raynaud's + arthritis (think antisynthetase)
• Unexplained ILD, especially in a younger patient or with accompanying weakness/rash
• Statin myopathy that doesn't resolve after stopping the statin (order anti-HMGCR separately)
• Dysphagia with proximal weakness

Do NOT Order For

• Mild CPK elevation after exercise or minor trauma
• Fibromyalgia or chronic fatigue without objective weakness
• Statin myalgias with normal or mildly elevated CPK that resolve after stopping the statin
• General screening in an ANA-positive patient without muscle or skin symptoms
• Vague complaints without clinical features supporting IIM

The Diagnostic Workflow for Primary Care

1. Recognize the presentation: progressive proximal weakness, elevated CPK, characteristic skin findings, or unexplained ILD.
2. First-line labs: CPK (with isoenzymes if available), aldolase, comprehensive metabolic panel (watch AST/ALT!), CBC, ESR/CRP, TSH, ANA.
3. If IIM is suspected: order the myositis-specific antibody panel. If statin-associated IMNM is suspected, also order anti-HMGCR separately.
4. Refer to rheumatology with labs in hand. Many patients will also need EMG, MRI of affected muscles, and potentially muscle biopsy for definitive diagnosis.
5. If anti-MDA5 is positive: urgent pulmonology referral for ILD evaluation—this can progress to respiratory failure rapidly.
6. If anti-TIF1γ or anti-NXP-2 is positive in an adult: comprehensive age-appropriate cancer screening at diagnosis.

Bottom Line

The myositis-specific antibody panel isn't just an academic exercise. Each antibody maps to a distinct clinical phenotype, predicts specific organ involvement, and changes management. Anti-MDA5 means you're racing against rapidly progressive ILD. Anti-TIF1γ means you're looking for hidden cancer. Anti-HMGCR means stopping the statin isn't going to be enough. Anti-Mi-2 means the prognosis is probably good.

Know your antibodies. Order the right test at the right time. And always check that CPK when the transaminases are up.

Stay sharp out there.